Video

Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma

Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Clinically meaningful activity was observed in a substantial number of patients in the trial, Ribas explains. The overall response rate by RECIST criteria was 38% with 90% of patients experiencing durable responses. At the highest dose, response was 52%. Most of the adverse events with lambrolizumab were minimal, Ribas suggests.

<<<

View more from the 2013 ASCO Annual Meeting

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Thach-Giao Truong, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Binod Dhakal, MD